Oral methotrexate for recurrent brain tumors in children: a Pediatric Oncology Group study.
Oral methotrexate for recurrent brain tumors in children: a Pediatric Oncology Group study.
复制标题
口服甲氨蝶呤治疗儿童复发性脑肿瘤:一项儿科肿瘤学小组研究。
DOI:
10.1097/00043426-200001000-00008
复制
发表时间:
2000
期刊:
影响因子:
--
通讯作者:
Kadota,RP
中科院分区:
文献类型:
--
作者:
Mulne,AF;Ducore,JM;Elterman,RD;Friedman,HS;Krischer,JP;Kun,LE;Shuster,JJ;Kadota,RP
Purpose:Children with recurrent or progressive central nervous system (CNS) tumors have an unfavorable prognosis. Based on Pediatric Oncology Group (POG) institutional pilot data, low-dose oral methotrexate (MTX) was studied.Methods:Eight dosages of MTX 7.5 mg/m 2 every 6 hours were administered on a weekly schedule for as long as 18 months. Patients in six different brain tumor strata were accrued.Results:The response rates (complete or partial responses) were as follows: astrocytoma 2 of 10, malignant glioma 1 of 19, medulloblastoma 0 of 18, brainstem tumor 0 of 12, ependymoma 1 of 7, and miscellaneous histologic types 0 of 12. The main toxicities, mucositis, myelosuppression, and hepatic transaminase elevation were considered tolerable.Conclusion:Low-dose oral MTX showed no significant activity against malignant glioma, medulloblastoma, brainstem tumors, and miscellaneous histologic types. Indeterminate but low response rates were observed in children with astrocytoma and ependymoma. This regimen will not be recommended for front-line therapy.
影响因子:
6.2
作者:
I. Djerassi;Jung Sun Kim;A. Reggev
通讯作者:
A. Reggev
影响因子:
11.2
作者:
D. Keefe;R. Capizzi;S. Rudnick
通讯作者:
S. Rudnick
影响因子:
45.3
作者:
J. C. Allen;R. Walker;Gerald Rosen
通讯作者:
Gerald Rosen